This 33-month project aims to deliver a step-change in Alzheimer’s disease (AD) patient engagement strategies and a paradigm shift from late-stage diagnosis to early-stage diagnosis. Multiple regional project sites will be established to identify and test models of efficient early identification of mild AD dementia and prodromal AD patients. These models will be compared and contrasted to identify ways to improve early detection and diagnosis of AD. The findings will enable models of patient access to be established and used in the broader AD community. Ultimately, MOPEAD will respond to the urgency of finding interventions to halt AD by stimulating a faster recruitment of patients into clinical trials. MOPEAD will contribute to the imperative to finding interventions to halt AD. Dementia affects over 35 million people globally, a figure set to rise to over 115 million by 2050 due to the ageing of the population. AD has a huge and growing burden on health and social systems, the families and carers of those affected. Despite decades of research, there is still no treatment nor cure for the disease. It is therefore crucial to determine interventions that will help identify hidden cases of AD through patient engagement and provide new insights for therapeutic interventions in clearly identified populations. MOPEAD partners are: Fundació ACE Institut Catala de Neurociencies Aplicades, Eli Lilly and Company Ltd, ASDM Consulting, AstraZeneca AB, European Institute of Women’s Health, GMV Soluciones Globales Internet S.A.U., Karolinska Institutet, KITE Innovation (Europe) Ltd, Spomincica—Alzheimer Slovenia, University Hospital of Cologne, University Medical Centre Ljubljana, Fundacio Hospital Universitari Vall D’Hebron—Institut de Recerca, Stichting VUmc, Alzheimer Europe.
F.22 Improvement to existing health/diagnostic methods/procedures